General Manager of CCRC Invited to Give a Speech at the South China Cardiac Intervention Forum 2023

The 2023 South China Cardiac Intervention Forum (SCIF 2023) and the South China Intraluminal Imaging and Functionality Summit Forum, as well as the Guangzhou Cardiac Intervention and Heart Failure Forum and the South China Heart Valve Intervention Elite Forum,is jointly organized by the Guangdong Society for Interventional Cardiology, the Guangdong Society for Health Management, the First Affiliated Hospital of Sun Yat sen University and Sun Yat sen Memorial Hospital of Sun Yat sen University. And Co organizing by the China Cardiovascular Imaging and Physiology Elite Club (CCEC), China Cardiovascular Innovation Club (CCI), the Structural Heart Disease Branch of the China Greater Bay Area Heart Association, Guangdong General Hospital, the First People’s Hospital of Foshan, Shenzhen People’s Hospital, and 7th People’s

Takeda’s Application for Marketing Authorization of the New Version of myPKFiT® in China is Officially Accepted by NMPA with the Help of CCRC

On October 7, 2023, the change of application for myPKFiT® (a pharmacokinetic-dosing software for Recombinant Human Coagulation Factor Ⅷ for Injection) submitted by Takeda, a leading biopharmaceutical company, was officially accepted by the National Medical Product Administration (NMPA), for which CCRC provided guidance throughout the entire product registration process. This new version includes an optimized app for healthcare professionals and an additional mobile app for patients. The myPKFiT® of Takeda is currently the only NMPA-approved personalized pharmacokinetic dosing software for prophylactic coagulation factor FVIII. It is intended to be used in combination with Recombinant Human Coagulation Factor Ⅷ for Injection of Takeda (firstly approved for marketing in China in 2013) to predict pharmacokinetics based on the values of the PK

[Good News] CCRC Help the First Self-Extending 3D Orthopedic Growth Guidance System Get FDA Designation as a Breakthrough Device!

CurvRITE Growth Guidance System developed by SpineGuide, a domestic medical device enterprise focusing on the research and development of spine products, obtained the FDA designation as a Breakthrough Device on Sep 11, 2023. CCRC is pleased to have helped SpineGuide to successfully tap into the U.S. market within the expected time frame. [The First Self-Extending 3D Orthopedic Growth Guidance System in the World] Scoliosis is a sideways curvature of the spine that most often is diagnosed in adolescents who are at rapid growth and development age, causing abnormal body appearance such as uneven backs and unequal shoulders. An especially serious spinal curve can reduce the amount of space within the chest, making it difficult for the heart and the lungs

Facilitate International Development, Boost Device Innovation – CCRC is Invited to Participate in the “Forum on Internationalization of Specialized Clinical Service CROs”

To improve the clinical service level of CROs in Shanghai and promote high-quality development of Shanghai biopharma industry, Shanghai Center for Biomedicine Development held the “Forum on Internationalization of Specialized Clinical Service CROs” under the guidance of Shanghai Municipal Commission of Economy and Informatization, Science and Technology Commission of Shanghai Municipality, and Shanghai Medical Products Administration, to provide a platform for industrial exchanges and discussions on boosting the development of Shanghai’s CRO industry. Mr. Guo Gongjian, Chairman of CCRC, and Ms. Yuan Qianhui, General Manager of CCRC were invited to participate in the forum as representatives of Shanghai medical device CROs. With the continuous progress of medical technology and the increased attention to peoples’ health worldwide, medical device enterprises and

Flagship Event in Biotechnology Industry! CCRC Looking Forward to Seeing You at 2023 Bio Asi

  CCRC invites you to join us at Booth M927, Floor 4, Hall 1, Taipei Nangang Exhibition Center from July 27th to 30th Jointly organized by the global Biotechnology Innovation Organization (BIO) and Taiwan Bio Industry Organization (Taiwan BIO), the 2023 BIO Asia International Conference and Exhibition will be held July 26-30, in Taipei, Taiwan. With an expected total of 750 leading companies to exhibit, 2,000 booths, 23 international forums, and numerous biotechnology professionals from more than 30 countries, the overall scale of BIO Asia this year will be even greater than that of the pre-pandemic conferences. As a leading CRO service company, CCRC sincerely invites you to visit us at Booth M927, Floor 4, Hall 1, Taipei Nangang Exhibition

Comprehensively Strengthening the Technological Innovation and Achievements Transformation in Neurosurgery — CCRC was invited to participate the ITMNS Innovation Training Program

Subtitle: To provide clinicians with a better understanding of the pathways of innovative technology transformation, build an innovative thinking framework, and further promote the exchanges of “industry, universities, research institutions, hospitals, policy After the publication of the “Healthy China 2030” blueprint, medical innovation and transformation have received much attention, and the state and medical institutions have been continuously increasing their investment in medical scientific research, and as a result, the reserve of medical innovation achievements has been continuously enriched. However, the transformation of scientific and technological innovation achievements to clinical application is obviously insufficient as neurosurgery related equipment and facilities are still dependent on import, and there is still a huge gap in independent innovation and transformation capacity of China